Professor, Radiation Oncology, Jefferson Medical College
Radiation Oncology
Dr. Adam P. Dicker, MD
|
|
Give Review
Adam Dicker works in the field of Radiation Oncology. He went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18/49 in Research/PrimaryCare. He over the years received 30 awards: "America's Top Doctors", "Philadelphia Magazine", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Philadelphias Top Docs (Radiation Oncology)", "Castle-Connolly America's Top Doctors for Cancer", "The Harvey Society", "Phillys Prostate Cancer Awareness", "Cancer Care Outstanding Service Award", "Travel grant", "Certificate of Recognition", "Certificate of Merit", "American Cancer Society Clinical Oncology Fellowship", "Dean's Research Award", "Vincent du Vigneaud Award of Excellence", "Upjohn Travel Award", "Dean's Research Prize", "Letter of Commendation", "Finalist", "William Morris Fellow", "Excellence in Medical Student Research", "George I. Ellis Award in Pharmacology", "Best M.D.-Ph.D. Presentation", "Louis and Rachel Rudin Foundation Fellow", "Robert Wood Johnson Jr. Charitable Trust Fellow", "Mayor's Volunteer Award", "Semifinalist, Westinghouse Talent Search Award", "First Prize, United States Navy Science Award", "First Prize, Society of Nuclear Medicine Award" and "Super Doctor". Dr. Adam P. Dicker is a published doctor. He published 97 publications, including: 'Quality and Reporting Accuracy of Phase 1 Drug Radiation Clinical Trials.' Adam Dicker accepts Medicare payments and is listed with Medicare.gov.
Publications
- Quality and Reporting Accuracy of Phase 1 Drug Radiation Clinical Trials.
- Evaluating the quality, clinical relevance, and resident perception of the radiation oncology in-training examination: A national survey.
- Assessing adverse events of postprostatectomy radiation therapy for prostate Cancer: evaluation of outcomes in the regione emilia-romagna, Italy.
- Novel actions of next-generation taxanes benefit advanced stages of prostate Cancer.
- Current Clinical Trials Testing Combinations of Immunotherapy and Radiation.
- Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' for prostate Cancer? an analysis of comparative effectiveness using published...
- RNA biomarkers associated with metastatic progression in prostate Cancer: a multi-institutional high-throughput analysis of SChLAP1.
- The retinoblastoma Tumor suppressor modulates DNA repair and radioresponsiveness.
- Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound.
- Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas.
- African-American Race Is a Predictor of Seminal Vesicle Invasion After Radical Prostatectomy.
- A TISSUE BIOMARKER BASED MODEL THAT IDENTIFIES PATIENTS WITH A HIGH RISK OF DISTANT METASTASIS AND DIFFERENTIAL SURVIVAL BY LENGTH OF ANDROGEN DEPRIVATION THERAPY IN R...
- A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.
- AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: Report of Task Group 192.
- African American men with low-grade prostate Cancer have increased disease recurrence after prostatectomy compared with Caucasian men.
- The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
- Genomic prostate Cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.
- Vorinostat as a radiosensitizer for Brain metastasis: a phase I clinical trial.
- The quality frontier.
- A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate Cancer.
- High-Priority Topics for Cancer Quality Measure Development: Results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit.
- Treatment-related complications of radiation therapy after radical Prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.
- Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
- Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomog...
- Phase I trials involving radiation therapy, quantifying the risks.
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult.
- A model to predict deflection of bevel-tipped active needle advancing in soft tissue.
- Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate Cancer.
- Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society f...
- Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate Cancer?
- High dose rate brachytherapy boost for prostate Cancer: A systematic review.
- Evolution of advanced technologies in prostate Cancer radiotherapy.
- Identification of a KRAS mutation in a patient with non-small cell lung Cancer treated with chemoradiotherapy and panitumumab.
- Polyacrylamide phantom for self-actuating needle-tissue interaction studies.
- The Responsibilities of a Chief Resident in Radiation Oncology: Results of a National Survey.
- Selectively starving Cancer cells through dietary manipulation: methods and clinical implications.
- Introduction: the changing landscape of prostate Cancer.
- Stereotactic body radiation therapy for prostate Cancer: is the technology ready to be the standard of care?
- Dietary recommendations during and after Cancer treatment: consistently inconsistent?
- RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients.
- ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK.
- Predictors of radiation oncology resident research productivity.
- Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features: Comparative Analysis of Long-term Outcomes.
- Radiotherapy Protocol Deviations and Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials.
- Impact of a Radiation Oncology Elective on the Careers of Young Physicians: Update on a Prospective Cohort Study.
- Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation.
- Association between metabolic syndrome, diabetes mellitus and prostate Cancer risk.
- Systematic review of hypofractionated radiation therapy for prostate Cancer.
- Nutrient restriction and radiation therapy for Cancer treatment: when less is more.
- Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study.
- Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States.
- Implementation and experimental results of 4D Tumor tracking using robotic couch.
- Reirradiation of recurrent meningioma.
- Pilot study of meaningful use of electronic health records in radiation oncology.
- Implanted dosimeters identify radiation overdoses during IMRT for prostate Cancer.
- A Phase I Study of the Combination of Sorafenib With Temozolomide and Radiation Therapy for the Treatment of Primary and Recurrent High-Grade Gliomas.
- Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies.
- Characterization and outcomes of optic nerve gliomas: a population-based analysis.
- The quality of cervical Cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective ...
- Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
- A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
- Can early implementation of salvage radiotherapy for prostate Cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiologic...
- mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate Cancer.
- Patient-oriented Cancer information on the internet: a comparison of wikipedia and a professionally maintained database.
- The meaning of p16 (ink4a) expression in Tumors: Functional significance, clinical associations and future developments.
- In reply to dr. King (adjuvant radiotherapy after Prostatectomy: does waiting for a detectable Prostate-specific antigen level make sense?).
- A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system maligna...
- Physician Beliefs and Practices for Adjuvant and Salvage Radiation Therapy After Prostatectomy.
- Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for th...
- Decreasing the adverse effects of Cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.
- Reliability of EUCLIDIAN: an autonomous robotic system for image-guided Prostate brachytherapy.
- Epidermal Growth Factor Receptor Expression Modulates AntiTumor Efficacy of Vandetanib or Cediranib Combined With Radiotherapy in Human Glioblastoma Xenografts.
- A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning i...
- Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.
- Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.
- Radiation dose-volume effects in the Brain.
- Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal Cancer xenograft model.
- Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos.
- Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
- Changes in gene expression predicting local control in cervical Cancer: results from Radiation Therapy Oncology Group 0128.
- Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
- Effect of percentage of positive Prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
- Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy.
- Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic Cancer.
- Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos.
- Efficacy and patterns of failure for locally advanced Cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
- VEGF trap in combination with radiotherapy improves Tumor control in u87 glioblastoma.
- Uncemented total hip arthroplasty in patients with a history of pelvic irradiation for prostate Cancer.
- A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical Cancer: primary endpoint analysis of RTOG 0128.
- Strategic plans to promote head and neck Cancer translational research within the radiation therapy oncology group: a report from the translational research program.
- Gene expression profiles as markers of aggressive disease-EGFR as a factor.
- In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model.
- Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos.
- Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling.
- Predicting the future from trials of the past: epidermal growth factor receptor expression and outcome of fractionated radiation therapy trials.
- Differentiation and definition of vascular-targeted therapies.
Schools
Joan Sanford I Weill Medical College Of Cornell University
Lenox Hill Hospital
Memorial Sloan Kettering Cancer Center
Procedures Preformed
- Brachytherapy
- External Beam Radiotherapy
- Image-Guided Radiation Therapy (IGRT)
- Intensity-Modulated Radiation Therapy (IMRT)
- View All
Conditions Treated
- Brain Cancer
- Brain Tumor
- Prostate Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Philadelphia’s Top Docs (Radiation Oncology)
- Castle-Connolly America's Top Doctors® for Cancer
- The Harvey Society
- Philly’s Prostate Cancer Awareness
- Cancer Care Outstanding Service Award
- Travel grant
- Certificate of Recognition
- Certificate of Merit
- American Cancer Society Clinical Oncology Fellowship
- Dean's Research Award
- Vincent du Vigneaud Award of Excellence
- Upjohn Travel Award
- Dean's Research Prize
- Letter of Commendation
- Finalist
- William Morris Fellow
- Excellence in Medical Student Research
- George I. Ellis Award in Pharmacology
- Best M.D.-Ph.D. Presentation
- Louis and Rachel Rudin Foundation Fellow
- Robert Wood Johnson Jr. Charitable Trust Fellow
- Mayor's Volunteer Award
- Semifinalist, Westinghouse Talent Search Award
- First Prize, United States Navy Science Award
- First Prize, Society of Nuclear Medicine Award
- Super Doctor
Education
-
Memorial Sloan-Kettering Cancer Center -
Weill Cornell Medical College of Cornell University
Hospital
-
Thomas Jefferson University Hospital
Drug Facts
| NPI NUMBER | 1558383984 | |
| NPPES Provider LastName | DICKER | |
| NPPES Provider FirstName | ADAM | |
| NPPES Provider ZIPCode | 191074824 | |
| NPPES Provider State | PA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 48.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558383984 |
| Last Name Of The Provider | DICKER |
| First Name Of The Provider | ADAM |
| View All |
Similar Doctors
|
Dr. Terry J. Styles, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wilhelm Lubbe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas G. Zaorsky, MD |
|
|
Dr. Caitlin A. Schonewolf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andre A. Konski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Gallagher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tithi Biswas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David B. Suh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Scot A. Fisher, DO |
|
Dr. Bizhan Micaily, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry Quon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey A. Geiger, MD
This Doctor is OpenDoctor Recommended.
|